Kidney disease caused by dysregulation of the complement alternative pathway: An etiologic approach

An S. De Vriese, Sanjeev M Sethi, Jens Van Praet, Karl A Nath, Fernando Custodio Fervenza

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Kidney diseases caused by genetic or acquired dysregulation of the complement alternative pathway (AP) are traditionally classified on the basis of clinical presentation (atypical hemolytic uremic syndrome as thrombotic microangiopathy), biopsy appearance (dense deposit disease andC3GN), or clinical course (atypical postinfectiousGN). Each is characterized by an inappropriate activation of the AP, eventuating in renal damage. The clinical diversity of these disorders highlights important differences in the triggers, the sites and intensity of involvement, and the outcome of the AP dysregulation. Nevertheless, we contend that these diseases should be grouped as disorders of the AP and classified on an etiologic basis. In this review, we define different pathophysiologic categories of AP dysfunction. The precise identification of the underlying abnormality is the key to predict the response to immune suppression, plasma infusion, and complement-inhibitory drugs and the outcome after transplantation. In a patient with presumed dysregulation of the AP, the collaboration of the clinician, the renal pathologist, andthe biochemical andgenetic laboratory is verymuch encouraged, because this enables the elucidation of both the underlying pathogenesis and the optimal therapeutic approach.

Original languageEnglish (US)
Pages (from-to)2917-2929
Number of pages13
JournalJournal of the American Society of Nephrology
Volume26
Issue number12
DOIs
StatePublished - Dec 1 2015

Fingerprint

Alternative Complement Pathway
Kidney Diseases
Thrombotic Microangiopathies
Membranoproliferative Glomerulonephritis
Kidney
Transplantation
Biopsy
Pharmaceutical Preparations
Therapeutics
Pathologists
Atypical Hemolytic Uremic Syndrome

ASJC Scopus subject areas

  • Nephrology

Cite this

Kidney disease caused by dysregulation of the complement alternative pathway : An etiologic approach. / De Vriese, An S.; Sethi, Sanjeev M; Van Praet, Jens; Nath, Karl A; Fervenza, Fernando Custodio.

In: Journal of the American Society of Nephrology, Vol. 26, No. 12, 01.12.2015, p. 2917-2929.

Research output: Contribution to journalArticle

@article{6dfdf4b094584b598a86580cb6ad8b8f,
title = "Kidney disease caused by dysregulation of the complement alternative pathway: An etiologic approach",
abstract = "Kidney diseases caused by genetic or acquired dysregulation of the complement alternative pathway (AP) are traditionally classified on the basis of clinical presentation (atypical hemolytic uremic syndrome as thrombotic microangiopathy), biopsy appearance (dense deposit disease andC3GN), or clinical course (atypical postinfectiousGN). Each is characterized by an inappropriate activation of the AP, eventuating in renal damage. The clinical diversity of these disorders highlights important differences in the triggers, the sites and intensity of involvement, and the outcome of the AP dysregulation. Nevertheless, we contend that these diseases should be grouped as disorders of the AP and classified on an etiologic basis. In this review, we define different pathophysiologic categories of AP dysfunction. The precise identification of the underlying abnormality is the key to predict the response to immune suppression, plasma infusion, and complement-inhibitory drugs and the outcome after transplantation. In a patient with presumed dysregulation of the AP, the collaboration of the clinician, the renal pathologist, andthe biochemical andgenetic laboratory is verymuch encouraged, because this enables the elucidation of both the underlying pathogenesis and the optimal therapeutic approach.",
author = "{De Vriese}, {An S.} and Sethi, {Sanjeev M} and {Van Praet}, Jens and Nath, {Karl A} and Fervenza, {Fernando Custodio}",
year = "2015",
month = "12",
day = "1",
doi = "10.1681/ASN.2015020184",
language = "English (US)",
volume = "26",
pages = "2917--2929",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "12",

}

TY - JOUR

T1 - Kidney disease caused by dysregulation of the complement alternative pathway

T2 - An etiologic approach

AU - De Vriese, An S.

AU - Sethi, Sanjeev M

AU - Van Praet, Jens

AU - Nath, Karl A

AU - Fervenza, Fernando Custodio

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Kidney diseases caused by genetic or acquired dysregulation of the complement alternative pathway (AP) are traditionally classified on the basis of clinical presentation (atypical hemolytic uremic syndrome as thrombotic microangiopathy), biopsy appearance (dense deposit disease andC3GN), or clinical course (atypical postinfectiousGN). Each is characterized by an inappropriate activation of the AP, eventuating in renal damage. The clinical diversity of these disorders highlights important differences in the triggers, the sites and intensity of involvement, and the outcome of the AP dysregulation. Nevertheless, we contend that these diseases should be grouped as disorders of the AP and classified on an etiologic basis. In this review, we define different pathophysiologic categories of AP dysfunction. The precise identification of the underlying abnormality is the key to predict the response to immune suppression, plasma infusion, and complement-inhibitory drugs and the outcome after transplantation. In a patient with presumed dysregulation of the AP, the collaboration of the clinician, the renal pathologist, andthe biochemical andgenetic laboratory is verymuch encouraged, because this enables the elucidation of both the underlying pathogenesis and the optimal therapeutic approach.

AB - Kidney diseases caused by genetic or acquired dysregulation of the complement alternative pathway (AP) are traditionally classified on the basis of clinical presentation (atypical hemolytic uremic syndrome as thrombotic microangiopathy), biopsy appearance (dense deposit disease andC3GN), or clinical course (atypical postinfectiousGN). Each is characterized by an inappropriate activation of the AP, eventuating in renal damage. The clinical diversity of these disorders highlights important differences in the triggers, the sites and intensity of involvement, and the outcome of the AP dysregulation. Nevertheless, we contend that these diseases should be grouped as disorders of the AP and classified on an etiologic basis. In this review, we define different pathophysiologic categories of AP dysfunction. The precise identification of the underlying abnormality is the key to predict the response to immune suppression, plasma infusion, and complement-inhibitory drugs and the outcome after transplantation. In a patient with presumed dysregulation of the AP, the collaboration of the clinician, the renal pathologist, andthe biochemical andgenetic laboratory is verymuch encouraged, because this enables the elucidation of both the underlying pathogenesis and the optimal therapeutic approach.

UR - http://www.scopus.com/inward/record.url?scp=84954040776&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954040776&partnerID=8YFLogxK

U2 - 10.1681/ASN.2015020184

DO - 10.1681/ASN.2015020184

M3 - Article

C2 - 26185203

AN - SCOPUS:84954040776

VL - 26

SP - 2917

EP - 2929

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 12

ER -